Literature DB >> 8928191

A colorimetric LDH assay for the titration of infectivity and the evaluation of anti-viral activity against ortho- and paramyxoviruses.

S Mori1, W Watanabe, S Shigeta.   

Abstract

A rapid and precise screening assay was developed for in vitro evaluation of anti-orthomyxo- and anti-paramyxovirus agents. The procedure is spectrophotometrical assessment for viability of cells via extracellular leakage of lactic dehydrogenase (LDH). HMV-II cells, a human melanoma cell line was found to be suitable for the titration of virus infectivity and screening of anti-viral agents for orthomyxo- and paramyxoviruses. Comparative titration of infectivity of stock viruses by the LDH and the MTT in site reduction of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) methods with HMV-II cells as well as plaque titration with MDCK, Vero and HeLa cells was carried out. The LDH method was comparable or more sensitive for influenza viruses (FLUV)-A, B, C, parainfluenza viruses (PFLUV)-1, 2 and less sensitive for PFLUV-3, mumps virus (MPSV), measles viruses (MLSV) and respiratory syncytial virus (RSV) than the plaque titration. The 50% effective concentration (EC50) of 1-beta-D-ribofuranosyl-1, 2, 4-triazol-3-carboxamide (ribavirin) and 5-ethynyl-1-beta-D-ribofuranosyl-imidazole-4-carboxamide (EICAR) against orthomyxo- and paramyxoviruses were examined comparatively by the LDH, MTT and plaque reduction (PR) methods. The EC50 values of FLUV-C and PFLUV-1 were able to be evaluated only by the LDH but not by the MTT and PR methods. The LDH method with HMV-II cells simplifies the assay procedure and permits the evaluation of a large number of compounds for anti-orthomyxo- and anti-paramyxoviruses activity in vitro.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8928191     DOI: 10.1620/tjem.177.315

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  5 in total

1.  Synergistic anti-influenza virus A (H1N1) activities of PM-523 (polyoxometalate) and ribavirin in vitro and in vivo.

Authors:  S Shigeta; S Mori; J Watanabe; S Soeda; K Takahashi; T Yamase
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

2.  Alteration of Liver Biomarkers in Patients with SARS-CoV-2 (COVID-19).

Authors:  Pourya Gholizadeh; Rohollah Safari; Parham Marofi; Elham Zeinalzadeh; Pasquale Pagliano; Khudaverdi Ganbarov; Silvano Esposito; Ehsaneh Khodadadi; Mehdi Yousefi; Hossein Samadi Kafil
Journal:  J Inflamm Res       Date:  2020-07-01

3.  Anti-RNA virus activity of polyoxometalates.

Authors:  Shiro Shigeta; Shuichi Mori; Toshihiro Yamase; Norio Yamamoto; Naoki Yamamoto
Journal:  Biomed Pharmacother       Date:  2006-05-24       Impact factor: 6.529

4.  Application of thermally responsive elastin-like polypeptide fused to a lactoferrin-derived peptide for treatment of pancreatic cancer.

Authors:  Iqbal Massodi; Emily Thomas; Drazen Raucher
Journal:  Molecules       Date:  2009-06-04       Impact factor: 4.411

Review 5.  Polyoxometalates active against tumors, viruses, and bacteria.

Authors:  Toshihiro Yamase
Journal:  Prog Mol Subcell Biol       Date:  2013
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.